Reversal of the antiaggregant effect of ticagrelor in combination with acetylsalicylic acid, using normal platelets

Paul Kruger

Research output: ThesisMaster's Thesis

76 Downloads (Pure)

Abstract

Ticagrelor, a platelet P2Y 12 receptor antagonist, decreases thrombotic events in patients with coronary artery disease but increases the risk of bleeding. All antidote is not yet available. Platelet transfusion has the potential to reverse the antiplatelet effect cl ticagrelor and reduce bleeding. This thesis reports on an in vitro study which shows that donor platelets increase the aggregation of tlcagrelor-treated platelets. The extent of the increase is determined by the time since the previous dose of ticagrelor and the quantity of donor platelets. Using the in vitro results, estimates of the effect of platelet transfusion on platelet aggregation are made.
Original languageEnglish
QualificationMasters
Awarding Institution
  • The University of Western Australia
Supervisors/Advisors
  • Eikelboom, John, Supervisor
  • Linden, Matthew, Supervisor
Thesis sponsors
Award date19 Dec 2019
DOIs
Publication statusUnpublished - 2019

Fingerprint

Dive into the research topics of 'Reversal of the antiaggregant effect of ticagrelor in combination with acetylsalicylic acid, using normal platelets'. Together they form a unique fingerprint.

Cite this